ESC 365 - Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish Heart Failure Registry

HFA Premium Access

Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish Heart Failure Registry

Session: Acute heart failure: treatment and prognosis

Topic: Pharmacotherapy

Speaker: Assistant Professor P. Becher (Hamburg, DE)

Event: Heart Failure 2022

Congress Presentation

Add to my library

About the speaker

Assistant Professor Peter Moritz Becher

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

0 follower

4 more presentations in this session

Role of urinary potassium to creatinine ratio for tailoring the type of diuretic regimen in patients with acute heart failure and diuretic resistance

Speaker: Doctor F. Croset (Madrid, ES)

Heart failure is the cancer for the heart: the prognostic importance of the new HLM classification

Speaker: Doctor A. D'Amato (Rome, IT)

Impact of obstructive sleep apnea in patients undergoing left ventricular assist device implantation

Speaker: Doctor N. Patel (Hartford, US)

Clinical, laboratory associates and prognostic significance of hypocapnia in acute heart failure.

Speaker: Mr M. Garus (Wroclaw, PL)

Access the full session

Acute heart failure: treatment and prognosis

Speakers: Assistant Professor P. Becher, Doctor F. Croset, Doctor A. D'Amato, Doctor N. Patel, Mr M. Garus

About the event

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources